> Repros Therapeutics saw its stock price jump on the news of positive data from a trial of its experimental therapy for uterine fibroid symptoms. Report
> The CEO of Sanofi-Aventis says he would buy a biotech company, if he could just find one with three or four products. Report
> Merck and Vertex started a mid-stage trial of MK-0457 for leukemia, triggering a $25 million milestone payment to Vertex. Report
> Point Therapeutics has finalized progression-free survival, survival and response data from its completed Phase II study of talabostat in combination with docetaxel in patients with Stage IIIB/IV non-small cell lung cancer. Release
> Critical Therapeutics announced that Frank E. Thomas has been promoted to the position of CEO. Release
> The FDA has approved Merck's INVANZ, a once-daily injectable antibiotic, for a new indication: The prophylaxis of surgical site infection following elective colorectal surgery in adults. Release
> Pherin Pharmaceuticals is reporting positive clinical trial results from a Phase II study of PH80 for treating symptoms of PMS. Release
> Bausch & Lomb has acquired the OTC allergy franchise of Alimera Sciences. Report
> The FDA has approved Anika's injectable soft-tissue filler. Report
And Finally…The Battelle National Biodefense Institute has been selected to run a national biological-threat lab in Maryland. Report